文献速递肿瘤 PET/CT核素与放射性配体治疗

短期非甾体雄激素拮抗剂治疗对激素敏感性前列腺癌PSMA表达及肿瘤细胞密度的影响:动态[68Ga]Ga-PSMA-11 PET/MR初步纵向前瞻性研究

The impact of short-term non-steroidal androgen antagonist therapy on PSMA expression and tumor cellularity studied with dynamic [68Ga]Ga-PSMA-11 PET/MR in hormone-sensitive prostate cancer patients, a preliminary longitudinal prospective study.
PubMed 文献 · EJNMMI Res · 2025-10-02

该初步纵向前瞻性研究在8例无骨转移的高危激素初治前列腺癌患者中,采用动态[68Ga]Ga-PSMA-11 PET与扩散加权MRI同步评估短期NSAA治疗对病灶PSMA表达(BPND)和细胞密度(ADC)的影响。结果显示7/8患者PSA显著下降(第28天中位倍数变化-88.3%),7个可检测摄取病灶的BPND呈非线性和非单调轨迹、治疗中期出现反弹,而所有病灶ADC值从基线进行性升高。静态SUV测量未能充分反映PSMA表达的动态变化,提示短期NSAA可诱导激素敏感性前列腺癌病灶的短暂PSMA上调。

要点

  • 短期NSAA治疗期间7/8患者PSA显著下降,第28天中位倍数变化-88.3%。
  • 8个可检测摄取病灶中7个BPND呈非单调轨迹,治疗中期出现反弹。
  • 所有病灶ADC值从基线进行性升高,提示肿瘤细胞密度降低。

核心结论

  • 短期NSAA在激素敏感性前列腺癌病灶中诱导短暂PSMA上调,尽管肿瘤细胞密度下降。
  • 该结果可能支持将短期NSAA与PSMA靶向治疗联合用于该人群。

研究设计与样本

  • 初步纵向前瞻性研究,纳入8例无骨转移的高危激素初治前列腺癌患者。
  • 采用动态[68Ga]Ga-PSMA-11 PET与扩散加权MRI同步估算结合潜力(BPND)和表观扩散系数(ADC)。

主要发现

  • 7/8患者出现血清PSA显著下降,第28天中位PSA倍数变化为-88.3%,提示自NSAA开始以来生化应答阳性。
  • 8个可检测[68Ga]Ga-PSMA-11摄取的病灶中,7个BPND呈非线性和非单调纵向轨迹,治疗中期出现反弹。
  • 所有病灶ADC值从基线进行性升高,提示随治疗进展肿瘤细胞密度降低。
  • 静态SUV测量未能充分反映PSMA表达的这些动态变化,敏感性有限。

临床怎么用

  • 在激素敏感性前列腺癌患者中,短期NSAA期间应关注PSMA表达的动态变化而非仅依赖静态SUV。
  • 动态[68Ga]Ga-PSMA-11 PET/MR联合ADC测量可用于评估NSAA对PSMA表达和肿瘤细胞密度的同步影响。

局限性

  • 本研究为初步研究,样本量小(8例患者、8个病灶),结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate-specific membrane antigen (PSMA) is overexpressed in most prostate cancers (PCa) and is targeted in both diagnostic and therapeutic applications. Preclinical studies suggest that short-term androgen blockade may upregulate PSMA expression, potentially enhancing lesion detectability with [68Ga]Ga-PSMA-11 positron emission computed tomography (PET) and the therapeutic efficacy of PSMA-targeted radioligands. However, clinical data remains limited and inconsistent. The aim of this study was to assess the impact of short-term non-steroidal androgen blockade therapy (NSAA) on lesion PSMA expression and cellularity using dynamic [68Ga]Ga-PSMA-11PET and diffusion-weighted magnetic resonance imaging (MR) for simultaneous estimation of binding potential (BPND) and apparent diffusion coefficient (ADC) in hormone-naïve patients with high-risk PCa without bone metastases. RESULTS: A significant serum prostate specific antigen (PSA) decline was observed in 7/8 patients (median PSA fold change - 88.3% at day 28), indicating positive biochemical response since the NSAA start. Among the observed eight lesions with detectable [⁶⁸Ga]Ga-PSMA-11 uptake, seven exhibited a non-linear and non-monotonic longitudinal trajectory of BPND, characterized by a rebound during the mid-treatment phase. In contrast, ADC values progressively increased from baseline for all lesions, suggesting reduced tumour cellularity as treatment progresses. Static SUV measurements poorly reflected these dynamic changes in PSMA expression, indicating limited sensitivity. CONCLUSION: Short-term NSAA induces transient PSMA upregulation in hormone-sensitive PCa lesions despite declining cellularity, which may support its cointegration to PSMA-targeted therapies for this population.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Sanchez-Crespo A, Jonmarker O, Jäderling F, et al. The impact of short-term non-steroidal androgen antagonist therapy on PSMA expression and tumor cellularity studied with dynamic [68Ga]Ga-PSMA-11 PET/MR in hormone-sensitive prostate cancer patients, a preliminary longitudinal prospective study. EJNMMI Res. 2025. PMID: 41039098. doi:10.1186/s13550-025-01328-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。